JSE listed stocks are selling at their cheapest levels in a decade.
And that's created an opportunity for internationally listed, and private equity companies to make a mint.
You see, these companies borrow money internationally at 3%, 4% or 5% interest. They then buy these South African companies that are selling cheaply and the dividends they receive from them are enough to repay their b... ››› more
Earlier today, the Public Investment Corporation (PIC) said that it is still opposed to the buyout of Adcock Ingram by CFR Pharmaceuticals. The PIC is resolute that it doesn't want shares in CFR as part of the deal. Let's take a closer look at what's going on…
On Sunday, the PIC rejected a revised bid by Chilean firm CFR. The PIC said that it is only interested in a cash only offer.
And the... ››› more
Earlier today, Adcock Ingram announced that about 45% of its shareholders were for a buyout by Chilean firm CFR Pharmaceuticals. Shares in Adcock rose on the news. After the chance of a buyout deal emerged nearly four months ago, the signs are still positive that it will go ahead. Let's take a closer look at what Adcock said today…
Adcock Ingram, South Africa’s second biggest drug maker, sai... ››› more
At the beginning of July, it emerged that Chilean firm, CFR Pharmaceuticals, had made an offer to buyout Adcock Ingram. Nearly four months down the line and it appears that some of the major shareholders in Adcock are in favour of the deal. Let's take a closer look at what's been going on...
On 11 September, it looked like the deal between Adcock Ingram and CFR Pharmaceuticals was edging towards... ››› more
Since the beginning of July, there has been a lot of interest in the potential buyout of Adcock Ingram by Chilean firm CFR Pharmaceuticals. CFR are now a step closer to making a binding offer for Adcock. Let's take a closer look at what's going on with the potential buyout…
The CEO of CFR, Chile’s largest drug maker, Alejandro Weinstein, said on Friday that CFR “will decide within weeks wh... ››› more
Earlier today, Adcock Ingram confirmed that it had received bids from other parties, but none could top CFR Pharmaceuticals offer. At the start of July, CFR made its move for Adcock. Let's have a closer look at what's been going on…
South Africa’s second largest pharmaceuticals company, Adcock Ingram said that it had “received some unsolicited bids from potential suitors,” reports Fin24.... ››› more
At the beginning of the month, Adcock Ingram received a buyout offer from a Chilean drug maker. This sent its share price soaring. Some shareholders in the company are already opposing the potential deal. Let's see what's going on…
The “biggest shareholder in Adcock Ingram” wants a local buyer for South Africa’s “second biggest drug maker,” reports Fin24. This follows a bid of over $... ››› more
Disclaimer Note that FSP Invest, a division of Fleet Street Publications (Pty) Ltd, is a research house and not a registered broker, financial advisor or financial service provider. Our editors and customer services teams also do not give personal investment advice. The advice in this website is general advice only and may not be appropriate to your particular investment objectives, financial situation or particular needs, so before investing or if in any doubt about your personal situation, you should seek professional advice from a stockbroker or independent financial adviser authorised by the Financial Services Board.
We research our recommendations and articles thoroughly, but disclaim all liability for any inaccuracies or omissions found in this publication.
Remember: Never invest more than you can afford to spare and that the value of any investment, and the income derived from it, can go down as well as up. The past is not necessarily a guide to future performance.
Editors or contributors may have an interest in investments commented on in this newsletter. However they have signed restraints to prevent the abuse of their position as contributors to this publication.